Reliable, Predictable, and Efficient Oncology Research
Cell Line-Derived Xenograft (CDX) Mouse Models
Our CDX Models Offer
Medicilon’s Cell Line-Derived Xenograft (CDX) Mouse Models provide a highly reliable and reproducible platform for evaluating anti-cancer therapies. With well-characterized tumor behavior, our CDX models support efficient preclinical drug screening, accelerating the development of targeted oncology treatments.
Broad Tumor Model Portfolio
Covering a diverse range of tumor cell lines, including lung, breast, colon, liver, and hematological malignancies.
High Reproducibility
Homogeneous tumor growth ensures reliable pharmacological evaluations.
Rapid Tumor growth
Facilitates quick and efficient in vivo drug screening.
Customized Study Design
Tailored models and treatment regimens to meet specific research needs.
CDX Applications in Oncology Drug Discovery
- Efficacy Studies – Evaluate the tumor-inhibitory effects of small molecules, biologics, and immunotherapies. Our pharmacodynamic (PD) models help assess efficacy and optimize therapeutic strategies.
- MOA Studies – Investigate drug interactions, resistance mechanisms, and biomarker discovery.
- Combination Therapy Testing – Assess synergistic effects of drug combinations for enhanced therapeutic efficacy.
Tumor
Neurological disease
Digestive system disease
Metabolic disease
Cardiovascular diseases
Inflammatory & immune disease
Other disease models
Humanized Models
Seamless Transition to PDX & Humanized Models
Medicilon provides a comprehensive suite of oncology models, including Patient-Derived Xenograft (PDX) and Humanized Mouse Models. Our solutions ensure a smooth transition from CDX preclinical validation to advanced translational research.
Tumor Models
Non-tumor Models
Research Model Types
Available CDX Models
Below is a detailed list of our CDX models. If you require a model that is not listed here, please check our cell line list or contact us. We can evaluate and validate a model for your specific needs.
Cancer Type
Cell Line
- Brain Cancer
- Breast Cancer
- Colon Cancer
- Endometrium
- Fibrosarcoma
- Gastric
Hs 746T, NCI-N87, SNU-16, MKN-45
- Head and Neck
TT, FaDu
- Leukemia
CCRF-CEM, HEL, HL-60, K-562, MV-4-11, THP-1, MOLT-4, MOLM-13, JVM-3
- Liver Cancer
Hep G2, HuH-7
- Lung Cancer
A549, Calu-1, Calu-3, Calu-6, HCC827, MOTO-211H, NCI-H1299, NCI-H1650, NCI-H1975, NCI-H2122, NCI-H2228, NCI-H292, NCI-H358, NCI-H460, NCI-H520, NCI-H526, NCI-H69, NCI-H727, PC9, NCI-H1581, NCI-H3122
- Lymphoma
SU-DHL-4, DB, SU-DHL-6, Mino, Daudi, JeKo-1, Raji, TMD-8, WSU DLCL2, DOHH2, OCI-LY19, OCI-HL10, U-937
- Melanoma
A375
- Myeloma
MM.1S, NCI-H929, RPMI-8226, OPM-2
- Osteosarcoma
SJSA-1
- Ovary
A2780, OVCAR-3, SK-OV-3
- Pancreatic
AsPC-1, Bx PC-3, Capan-1, Capan-2, CFPAC-1, HPAF-II, Mia PaCa-2, PANC-1, SU.86.86, SW1990
- Prostate
DU145, PC-3, LnCap
- Renal
786-O, OS-RC-2, A498, ACHN
- Skin
A-431
- Urinary bladder Cancer
RT4, UM-UC-3
Ocular Disease Models
Ophthalmic disease models for specialized research
Animal models for:
Conjunctival tissue proliferation and NV
Diabetic retinopathy (DR)
Choroidal neovascularization (CNV) and subretinal fibrosis
Corneal neovascularization (Corneal NV)
Acute ocular inflammation models
Dry Eye
